| Optimum Balance | |
|
1537 N. Leroy Street Suite D Fenton MI 48430 | |
| (810) 771-8969 | |
| Not Available |
| Full Name | Optimum Balance |
|---|---|
| Speciality | Clinic/Center |
| Location | 1537 N. Leroy Street, Fenton, Michigan |
| Authorized Official Name and Position | Karl Stanley Gill (OWNER) |
| Authorized Official Contact | 8107718969 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Optimum Balance 1537 N Leroy St Ste D Fenton MI 48430-2795 Ph: (810) 771-8969 | Optimum Balance 1537 N. Leroy Street Suite D Fenton MI 48430 Ph: (810) 771-8969 |
| NPI Number | 1245767888 |
|---|---|
| Provider Enumeration Date | 05/14/2017 |
| Last Update Date | 09/17/2020 |
| Certification Date | 09/17/2020 |
| Medicare PECOS PAC ID | 9739418351 |
|---|---|
| Medicare Enrollment ID | O20190906003138 |
News Archive
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Pioneering neural recordings in patients with Parkinson's disease by UC San Francisco scientists lays the groundwork for personalized brain stimulation to treat Parkinson's and other neurological disorders.
On Friday, the Department of Health and Human Services rejected Texas' request to delay implementation of the health law's medical-loss ratio requirement.
Johns Hopkins researchers report the discovery of a molecular switch that regulates the behavior of a protein that, when altered, is already known to increase human susceptibility to schizophrenia and mood disorders.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245767888 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QM0801X | Clinic/center - Mental Health (including Community Mental Health Center) | 6401013238 (Michigan) | Primary |
| Provider Name | Joseph Dragun |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1093789448 PECOS PAC ID: 1355321845 Enrollment ID: I20040724000029 |
News Archive
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Pioneering neural recordings in patients with Parkinson's disease by UC San Francisco scientists lays the groundwork for personalized brain stimulation to treat Parkinson's and other neurological disorders.
On Friday, the Department of Health and Human Services rejected Texas' request to delay implementation of the health law's medical-loss ratio requirement.
Johns Hopkins researchers report the discovery of a molecular switch that regulates the behavior of a protein that, when altered, is already known to increase human susceptibility to schizophrenia and mood disorders.
› Verified 4 days ago
| Provider Name | Lawrence R Koper |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1134482573 PECOS PAC ID: 8022251628 Enrollment ID: I20130829000684 |
News Archive
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Pioneering neural recordings in patients with Parkinson's disease by UC San Francisco scientists lays the groundwork for personalized brain stimulation to treat Parkinson's and other neurological disorders.
On Friday, the Department of Health and Human Services rejected Texas' request to delay implementation of the health law's medical-loss ratio requirement.
Johns Hopkins researchers report the discovery of a molecular switch that regulates the behavior of a protein that, when altered, is already known to increase human susceptibility to schizophrenia and mood disorders.
› Verified 4 days ago
| Provider Name | Joshua Fortney |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1073854576 PECOS PAC ID: 7719382795 Enrollment ID: I20210830002084 |
News Archive
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Pioneering neural recordings in patients with Parkinson's disease by UC San Francisco scientists lays the groundwork for personalized brain stimulation to treat Parkinson's and other neurological disorders.
On Friday, the Department of Health and Human Services rejected Texas' request to delay implementation of the health law's medical-loss ratio requirement.
Johns Hopkins researchers report the discovery of a molecular switch that regulates the behavior of a protein that, when altered, is already known to increase human susceptibility to schizophrenia and mood disorders.
› Verified 4 days ago
| Provider Name | Kimberly Marie Sanderson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1659044683 PECOS PAC ID: 9133584907 Enrollment ID: I20230501000433 |
News Archive
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Pioneering neural recordings in patients with Parkinson's disease by UC San Francisco scientists lays the groundwork for personalized brain stimulation to treat Parkinson's and other neurological disorders.
On Friday, the Department of Health and Human Services rejected Texas' request to delay implementation of the health law's medical-loss ratio requirement.
Johns Hopkins researchers report the discovery of a molecular switch that regulates the behavior of a protein that, when altered, is already known to increase human susceptibility to schizophrenia and mood disorders.
› Verified 4 days ago
| Provider Name | Teresa Traks-garrison |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1659972297 PECOS PAC ID: 2567815558 Enrollment ID: I20240125003496 |
News Archive
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Pioneering neural recordings in patients with Parkinson's disease by UC San Francisco scientists lays the groundwork for personalized brain stimulation to treat Parkinson's and other neurological disorders.
On Friday, the Department of Health and Human Services rejected Texas' request to delay implementation of the health law's medical-loss ratio requirement.
Johns Hopkins researchers report the discovery of a molecular switch that regulates the behavior of a protein that, when altered, is already known to increase human susceptibility to schizophrenia and mood disorders.
› Verified 4 days ago
News Archive
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.
Pioneering neural recordings in patients with Parkinson's disease by UC San Francisco scientists lays the groundwork for personalized brain stimulation to treat Parkinson's and other neurological disorders.
On Friday, the Department of Health and Human Services rejected Texas' request to delay implementation of the health law's medical-loss ratio requirement.
Johns Hopkins researchers report the discovery of a molecular switch that regulates the behavior of a protein that, when altered, is already known to increase human susceptibility to schizophrenia and mood disorders.
› Verified 4 days ago
Room To Reflect Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 785 1st St, Fenton, MI 48430 Phone: 248-563-9336 | |
Deanna Fletcher Lmsw Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1122 N Leroy St Ste A, Fenton, MI 48430 Phone: 810-215-1414 | |
Ebb & Flow Aba Therapy Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2084 W Thompson Rd Ste 500, Fenton, MI 48430 Phone: 810-429-0248 | |
P. Douglas Callan & Assoc Ltd Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1361 N Long Lake Rd, Fenton, MI 48430 Phone: 810-629-6549 Fax: 810-629-0614 | |
Day One Counseling & Consulting, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 14165 N Fenton Rd Ste 102f, Fenton, MI 48430 Phone: 810-287-5169 | |
Hidden Within Counseling & Sex Therapy Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 702 Georgetown Pkwy, Fenton, MI 48430 Phone: 810-214-0133 | |
Tlp Counseling & Therapy, Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 11445 Bay Of Firth Blvd, Fenton, MI 48430 Phone: 810-610-3312 |